Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: intervention time series analysis.

Publication date: Feb 01, 2024

To determine the impact of the COVID-19 pandemic on antimicrobial consumption and trends of therapeutic drugs for COVID-19 treatments, including corticosteroids, remdesivir and monoclonal antibodies (tocilizumab) from April 2017 to September 2022 in a secondary care NHS Trust in England. A retrospective intervention time series analysis was conducted for April 2017 to September 2022 at the Mid Yorkshire Teaching NHS Trust. Data were retrieved from the pharmacy dispensing system as defined daily doses (DDDs) monthly and reported per 1000 occupied bed days (OBDs). Antimicrobial consumption and COVID-19 treatment options were measured. DDDs were calculated according to the classification of antimicrobials for systemic use (J01) and for other drugs classification. Trends for antimicrobial consumption and other therapeutic drugs for treating COVID-19 were also determined in each wave in England. During the pandemic: total antibiotic consumption decreased from 826. 4 to 728. 2 DDDs per 1000 OBDs (Pā€Š=ā€Š0. 0067); piperacillin/tazobactam use increased (Pā€Š

Concepts Keywords
Antibiotic Antimicrobial
Bed April
Monthly Classification
September Consumption
Yorkshire Covid


Type Source Name
disease MESH COVID-19 pandemic
disease IDO intervention
disease VO time
drug DRUGBANK Tocilizumab
disease VO monthly
drug DRUGBANK Piperacillin
drug DRUGBANK Tazobactam

Original Article

(Visited 1 times, 1 visits today)